Myeloperoxidase (MPO) - p-ANCA
The Myeloperoxidase (MPO) - p-ANCA biomarker measures the level of antibodies against myeloperoxidase, an enzyme found in neutrophils, which is often elevated in certain types of vasculitis and other inflammatory conditions.
MPO-pANCA is a diagnostic biomarker for vasculitis and inflammatory conditions.
Key facts at a glance
- Units
- U/mL
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- Roche MPO-ANCA, Abbott MPO-ANCA, Euroimmun MPO-ANCA
The Myeloperoxidase (MPO) - p-ANCA biomarker is used to detect the presence of anti-myeloperoxidase antibodies, which are characteristic of several autoimmune conditions, particularly microscopic polyangiitis and granulomatosis with polyangiitis.
Elevated levels of MPO-pANCA are often associated with systemic vasculitis, glomerulonephritis, and other inflammatory disorders, making it a crucial diagnostic tool for these conditions.
The reference range for MPO-pANCA is typically between 0–20 U/mL, and levels above this range may indicate the presence of an underlying inflammatory or autoimmune condition.
Frequently asked questions
What conditions can cause elevated MPO-pANCA levels?
How is the MPO-pANCA test performed?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy